Penumbra, Inc.
PENPenumbra, Inc. is a global healthcare company specializing in innovative medical devices for neurovascular, peripheral vascular, and other neurological procedures. Founded in 2004, the company focuses on developing advanced solutions to improve patient outcomes and enhance procedural efficiency in minimally invasive treatments. Penumbra’s product portfolio includes devices for clot removal, aneurysm management, and vascular access, emphasizing technology-driven approaches in neurovascular and peripheral interventions.
Company News
GuideAI Health Corp. announced the appointment of renowned interventional radiologist Dr. James Benenati, Chief Medical Officer of Penumbra Inc., to its Advisory Board following FDA 510(k) clearance of its VAOT software. VAOT is an AI-based triage tool designed to assist radiologists in identifying peripheral arterial disease and vascular occlusi...
The global microcatheter market is valued at USD 1.05 billion in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by increasing adoption of minimally invasive cardiovascular and neurovascular procedures, rising prevalence of cardiovascular and neurovascular disorders, and advancements in cath...
Champlain Investment Partners completely exited its position in ServisFirst Bancshares, selling 1.57 million shares worth approximately $124.23 million. However, the exit appears to be part of broader fund downsizing rather than a targeted judgment on the company, as Champlain's reportable AUM contracted by roughly $2 billion quarter-over-quarter...
Boston Scientific is well-positioned to capitalize on global aging demographics, with products addressing age-related conditions like atrial fibrillation, chronic pain, and Parkinson's disease. Recent acquisitions of Penumbra and Silk Road Medical expand its stroke treatment capabilities. Despite strong fundamentals and double-digit growth, the s...
Investor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.
